Literature DB >> 2001456

Molecular characterization of beta-thalassemia intermedia in patients of Italian descent and identification of three novel beta-thalassemia mutations.

S Murru1, G Loudianos, M Deiana, C Camaschella, G V Sciarratta, S Agosti, M I Parodi, P Cerruti, A Cao, M Pirastu.   

Abstract

In this study, we have defined by dot-blot analysis with allelic specific oligonucleotide probes or direct sequencing on amplified DNA the beta-thalassemia mutations in a large group of patients (23) of Italian descent with thalassemia intermedia. These patients had one parent with either the silent beta-thalassemia carrier phenotype or borderline-normal hemoglobin A2 (HbA2) levels (2.5% to 3.5%). Nearly all were genetic compounds for a severe beta-thalassemia mutation and a beta-thalassemia mutation associated with high residual output of beta-globin chains (beta + intervening sequence [IVS]-I-nt6, beta -87, beta -101), indicating that inheritance of a mild beta-thalassemia allele, even in a single dose, is the most common molecular mechanism producing thalassemia intermedia in the Italian population. In three cases, in whom we failed to define by dot-blot analysis the mutations, we sequenced the beta + globin gene and found three novel beta-thalassemia mutations, which are certainly very rare because they have been hitherto detected solely in a single patient. These mutations consist of: (1) a T-A substitution at position 2 of IVS-I, in a patient compound heterozygote for this mutation and the -87 promoter mutation; (2) a G-C substitution at position 844 of IVS-II, in a patient heterozygous for this mutation who showed normal sequences at the in trans beta-globin gene (The reason for the presence of clinical manifestations in a beta-thalassemia heterozygote has not been defined.); and (3) a deletion of one nucleotide (-T) at codon 126, resulting in a frameshift and readthrough of the 5' untranslated region and most likely producing an elongated Hb molecule of 156 amino acid residues, in a patient heterozygous for this mutation with normal beta-globin gene sequences at the other locus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2001456

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Clinical heterogeneity of silent-gene b-thalassemia among Indians.

Authors:  A Nadkarni; A Pawar; V C Mudera; D Mohanty; R Colah
Journal:  Ann Hematol       Date:  1995-01       Impact factor: 3.673

2.  X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene.

Authors:  S W Knight; N S Heiss; T J Vulliamy; S Greschner; G Stavrides; G S Pai; G Lestringant; N Varma; P J Mason; I Dokal; A Poustka
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

3.  Splicing mutation in the ATR-X gene can lead to a dysmorphic mental retardation phenotype without alpha-thalassemia.

Authors:  L Villard; A Toutain; A M Lossi; J Gecz; C Houdayer; C Moraine; M Fontès
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

4.  The molecular basis of beta-thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity.

Authors:  Wanqun Chen; Xinhua Zhang; Xuan Shang; Ren Cai; Liyan Li; Tianhong Zhou; Manna Sun; Fu Xiong; Xiangmin Xu
Journal:  BMC Med Genet       Date:  2010-02-25       Impact factor: 2.103

5.  Thalassemia intermedia: compound heterozygous beta zero/beta(+)-thalassemia and co-inherited heterozygous alpha(+)-thalassemia.

Authors:  A E Kulozik; E Kohne; E Kleihauer
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

6.  Hb S/β-Thalassemia in the REDS-III Brazil Sickle Cell Disease Cohort: Clinical, Laboratory and Molecular Characteristics.

Authors:  André R Belisário; Anna B Carneiro-Proietti; Ester Cerdeira Sabino; Aderson Araújo; Paula Loureiro; Cláudia Máximo; Miriam V Flor-Park; Daniela D O W Rodrigues; Mina Cintho Ozahata; Christopher McClure; Rosimere Afonso Mota; Isabel C Gomes Moura; Brian Custer; Shannon Kelly
Journal:  Hemoglobin       Date:  2020-03-16       Impact factor: 0.849

Review 7.  The molecular basis of β-thalassemia.

Authors:  Swee Lay Thein
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

8.  Sickle cell anemia, sickle cell beta-thalassemia, and thalassemia major in Albania: characterization of mutations.

Authors:  E Boletini; M Svobodova; V Divoky; E Baysal; M A Cürük; A J Dimovski; R Liang; A D Adekile; T H Huisman
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

9.  A T to G mutation in the polypyrimidine tract of the second intron of the human beta-globin gene reduces in vitro splicing efficiency: evidence for an increased hnRNP C interaction.

Authors:  P Sébillon; C Beldjord; J C Kaplan; E Brody; J Marie
Journal:  Nucleic Acids Res       Date:  1995-09-11       Impact factor: 16.971

10.  Very mild forms of Hb S/beta(+)-thalassemia in Brazilian children.

Authors:  André Rolim Belisário; Rahyssa Rodrigues Sales; Marcos Borato Viana
Journal:  Rev Bras Hematol Hemoter       Date:  2015-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.